What are the recent trends in market size and growth for the taltz market?
The taltz market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased prevalence of psoriasis and psoriatic arthritis, increased adoption of biologics in treatment, high awareness in developed regions, expansion of healthcare infrastructure, and early regulatory approvals in key markets.
The taltz market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to the increasing prevalence of autoimmune diseases, rising healthcare expenditure globally, government initiatives for chronic disease management, expansion in emerging markets, growing adoption of personalized medicine. Major trends in the forecast period include a shift toward self-administration biologics, technological innovations in drug formulation, strategic collaborations and licensing agreements, advancements in biologic drug delivery, growth in biosimilar competition.
Get Your Free Sample of The Global Taltz Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20308&type=smp
How have varous drivers impacted the growth of the taltz market?
The rising prevalence of autoimmune diseases is expected to drive the taltz market going forward. Autoimmune diseases refer to conditions in which the body’s immune system mistakenly attacks its own healthy cells and tissues, leading to inflammation and damage. Autoimmune diseases are rising due to factors such as genetic predisposition, environmental triggers, lifestyle changes, and advancements in diagnostic techniques leading to better identification and awareness of these conditions. Taltz is used to treat autoimmune diseases as it targets and inhibits specific inflammatory pathways, particularly interleukin-17A, to reduce inflammation and relieve symptoms associated with conditions such as psoriasis and psoriatic arthritis. For instance, in August 2022, according to the National Library of Medicine, a US-based medical library, in 2022, a systematic review of 464 studies identified 928 cases of autoimmune conditions associated with COVID-19 vaccination. Of these, 81.5% (756 cases) were new-onset autoimmune diseases, with symptoms usually emerging eight days post-vaccination. Most affected individuals were women (53.6%), with a median age of 48 years. Therefore, the growing prevalence of autoimmune disorders will drive the growth of the taltz market.
What are the primary segments of the taltz market?
The taltz market covered in this report is segmented –
1) By Indication: Psoriasis; Psoriatic Arthritis; Ankylosing Spondylitis
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End User: Pediatric; Adult
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/taltz–global-market-report
Which firms are leading the taltz market?
Major companies operating in the taltz market are Eli Lilly and Company
How will industry trends affect the trajectory of the taltz market?
The key trend in the taltz market is securing drug approval from regulatory authorities to achieve a competitive advantage in the industry. Drug approval involves the evaluation and authorization of a new drug by regulatory bodies, ensuring its safety, effectiveness, and quality based on clinical trial data. For instance, in August 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched a new citrate-free formulation of Taltz (ixekizumab) injection with a concentration of 80 mg/mL. This new version received approval from the U.S. Food and Drug Administration (FDA) in May 2022. While it contains the same active ingredient as the original formulation, the updated version is specifically designed to significantly reduce pain at the injection site. Clinical data indicated an 86% reduction in pain, as measured on a visual analog scale (VAS), in comparison to the original formulation. Taltz is approved for use in adults and children aged six and older who have moderate to severe plaque psoriasis and are candidates for systemic therapy or phototherapy. Additionally, it is indicated for adults with active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis that show objective signs of inflammation.
Which geographic trends are shaping the taltz market, and which region has the highest market share?
North America was the largest region in the taltz market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the taltz market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Taltz Market Report 2025 Offer?
The taltz market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Taltz (ixekizumab) is a prescription biologic medication, primarily used to treat autoimmune conditions such as moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a monoclonal antibody that targets interleukin-17A (IL-17A), a protein involved in inflammatory responses, helping to reduce symptoms like joint pain, skin lesions, and stiffness.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20308
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
